NCCHCA Member Login

test

Therapeutics Standing Orders

SWSO IV REGEN_COV Final signed 1.5.22

SWSO IV Sotrovimab Final signed 1.5.22

SWSO SQ REGEN_COV Final signed 1.5.22

SWSO IV BAM-ETE Final signed 1.5.22

Surveillance Data Beyond the DHHS Dashboard

We previously shared a link to CLI (COVID Like Illness) data that contains more detailed information than what is offered on the State’s dashboard. This data is updated every Tuesday by 4pm and can be found here.

Monoclonal Antibody Therapy (mAb)

Summary document of mAb therapy: Monoclonal Antibody Summary.

Use this link for more detailed information regarding mAb. *Please note: the published rates may not apply to Medicaid and the uninsured. We are currently working to verify this.

DHHS has provided the following fliers to communicate with your patients regarding the availability of mAb (whether you are administering the therapy or not) mAb Patients English    mAb Patients Spanish

NOTE As of 9/10: The U.S. Department of Health and Human Services (HHS)  has executed a ninth amendment to the Public Readiness and Emergency Preparedness (PREP) Act Declaration that expands the pool of professionals now covered under the Act for the administration of COVID-19 monoclonal antibody therapeutics. Specifically, the recent amendment includes coverage of licensed pharmacists, pharmacy technicians, and pharmacy interns when administering COVID-19 monoclonal antibody therapeutics orally, through intramuscular injection, or through subcutaneous injection.

Medication Warnings:

North Carolina DHHS Ivermectin Notice – final

NCDHHS requests communications assistance around Invermectin:

Due to a recent spike in prescriptions for ivermectin (an antiparasitic drug), related poison control calls and emergency room visits, NCDHHS is informing all providers that ivermectin is neither approved nor authorized by the FDA to treat or prevent COVID-19. The National Institutes of Health (NIH) has determined there is insufficient data to recommend for or against ivermectin for treatment of COVID-19. Exercise caution when prescribing this drug outside of authorized treatment avenues.

We need your help. Please educate your patients about the risks of using ivermectin without a prescription and the potential risks of use for the prevention or treatment of COVID-19. Talking points for providers are included in this communication. Further information is available in the CDC Health Advisory on Ivermectin Use to Prevent or Treat COVID-19.

Talking points for Clinicians and Public Health Practitioners:

COVID-19 Planning Resources

 

Marketplace Open Enrollment Starts Nov. 1

Speak with an enrollment assister to explore your health insurance options!

¡Hable con un asistente de inscripción para explorar sus opciones de seguro médico!

 

 

learn more / aprende más